MedTrace Logo

Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC

NCT07724886 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 732

Last updated 2026-08-03

No results posted yet for this study

Summary

This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-year BCG therapy, in patients with intermediate-risk or high-risk NMIBC.

Conditions

Interventions

PROCEDURE

Conventional Transurethral Resection of Bladder Tumour

Conventional TURBT is performed by resecting the bladder tumour in a piecemeal manner with a top-down approach. The bladder tumour specimen is fragmented during the procedure and whether a complete resection has been achieved is determined by the operating surgeon's judgment intra-operatively.

PROCEDURE

Transurethral En Bloc Resection of Bladder Tumour

This surgical technique resects the bladder tumour underneath the submucosal plane, and the bladder tumour can be removed in one piece.

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Yuen Chun Jeremy TEOH, MD · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2029-12-31
Completion
2030-03-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07724886 on ClinicalTrials.gov